Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- (-) Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 90 Results
Valuing Innovation in the Current and Post-Pandemic World
Biopharmaceutical industry experts gathered for a panel discussion at the eyeforpharma Virtual Conference to explore how the value of innovation, productivity and preparedness might change as a…
In Social Distancing, Finding Closeness in Community
In a video, National Pharmaceutical Council President and CEO Dan Leonard discusses social distancing and the importance of community during the COVID-19 pandemic.
What's Really Behind Discrepancies in Coverage Decisions?
National Pharmaceutical Council President and CEO Dan Leonard discusses research that uncovers the reasons for discrepancies in coverage decisions.
NPC Submits Comments on Cures 2.0
The National Pharmaceutical Council (NPC) submitted comments in response to a public request for input on Cures 2.0, an “effort to modernize coverage and access to life-saving cures in the United…
Current Landscape: Value Assessment Frameworks
This report analyzed seven existing U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework.
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…
NPC in Specialty Pharmacy Times: Why We Need to Consider the Proven Value of Drug Therapies
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explores recent research from the NPC and RTI Health…
NPC in Specialty Pharmacy Times: International Drug Pricing Index Model Could Restrict Innovation, Access
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over…
Integrating Data for Better Care Management
To accelerate the ability of care management programs to use data to combat rising health care costs, while ensuring patient access to innovative treatments that can improve outcomes, NPC sponsored…
NPC in Specialty Pharmacy Times: How Can We Advance Progress in Moving from Volume to Value in Health Care?
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a…
NPC in Chain Drug Review: Preserving the Proven Impact of Biopharmaceutical Innovation
In his latest commentary for Chain Drug Review, NPC President and Chief Executive Officer Dan Leonard considers the challenges in measuring and paying for value in health care, particularly when it…
Get to Know Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD
Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD, sat down with us to discuss her upcoming research, bridging the gap between academia and health care stakeholders, tips for…
NPC in Morning Consult: Does High Return Call for Greater Investment?
In his latest commentary for Morning Consult, NPC Chief Science Officer Robert W. Dubois explores new research that sheds light on which types of medical care have provided the greatest overall…
FDA Clarifies What Information Can Be Exchanged With Health Decision-Makers
With the release of two guidance documents this week, the US Food and Drug Administration took significant steps to modernize how health care information is communicated. The final guidance released…
What’s Next in Precision Medicine?
Personalized medicine is greatly changing health care practices, as well as how innovative treatments are being developed.
National Pharmaceutical Council President Dan Leonard in Specialty Pharmacy Times: How Do We Pay for Medical Innovation?
In this month's Specialty Pharmacy Times, National Pharmaceutical Council President Dan Leonard says it’s time to think differently about how we pay for health care and assess value and benefits.
A Focus on Patients, Innovation on Rare Disease Day
February 28 is Rare Disease Day, highlighting both the progress made to date in developing treatments for rare diseases, as well as how much work remains to be done. Nearly one in 10 Americans…